Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE: Repotrectinib in pediatric and young adult subjects with ALK, ROS1, or NTRK-altered advanced malignancies
2019-003055-11Phase 2Active
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of repotrectinib in Non-hematologic malignancy, advanced nonhematological malignancy, Metastatic solid neoplasm and 1 more, sponsored by Turning Point Therapeutics, Inc. Primary endpoints: Duration of response (DOR), Overall survival (OS) and 1 more. Started Dec 2022; status: active.
02
Drugs
repotrectinib
03
Conditions
Non-hematologic malignancyadvanced nonhematological malignancyMetastatic solid neoplasmcancer
Beyond the preview
Go deeper on 2019-003055-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003055-11.